Compare Stocks → The Greatest LEGAL Transfer of Wealth in History is Underway (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare ShareLink copied to clipboard. NASDAQ:GRTXNASDAQ:IMCCNASDAQ:MTEXNASDAQ:PRPO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRTXGalera Therapeutics$0.11+8.9%$0.17$0.09▼$3.59$5.85M2.042.06 million shs266,260 shsIMCCIM Cannabis$0.46-5.1%$0.68$0.19▼$1.35$6.19M0.5991,426 shs43,997 shsMTEXMannatech$8.00+3.2%$8.01$7.30▼$15.10$15.04M1.17427 shs555 shsPRPOPrecipio$5.61-2.4%$6.10$4.75▼$9.97$8.25M1.275,638 shs708 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRTXGalera Therapeutics-9.45%-31.93%-43.95%-54.45%-96.94%IMCCIM Cannabis+6.85%-12.95%-32.03%+60.97%-55.36%MTEXMannatech-2.41%+0.80%-4.91%-11.58%-39.52%PRPOPrecipio+1.23%0.00%-4.72%-9.16%-39.54%Nvidia’s Quiet $1 Trillion Pivot (Ad)Nvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGRTXGalera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIMCCIM CannabisN/AN/AN/AN/AN/AN/AN/AN/AMTEXMannatech0.1085 of 5 stars0.03.00.80.00.02.50.0PRPOPrecipio0.6648 of 5 stars2.05.00.00.00.60.80.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRTXGalera Therapeutics1.75ReduceN/AN/AIMCCIM CannabisN/AN/AN/AN/AMTEXMannatechN/AN/AN/AN/APRPOPrecipioN/AN/A$40.00613.01% UpsideCurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/AIMCCIM Cannabis$36.15M0.17N/AN/A$0.76 per share0.61MTEXMannatech$131.96M0.11N/AN/A$5.64 per share1.42PRPOPrecipio$15.20M0.54N/AN/A$10.16 per share0.55Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRTXGalera Therapeutics-$59.08M-$0.99N/A∞N/AN/AN/A-138.81%8/12/2024 (Estimated)IMCCIM Cannabis-$7.04M-$0.80N/AN/AN/A-28.03%-75.51%-24.18%8/12/2024 (Estimated)MTEXMannatech-$2.24M-$0.89N/A∞N/A-1.31%-15.37%-3.92%8/12/2024 (Estimated)PRPOPrecipio-$5.85M-$3.42N/A∞N/A-31.00%-46.12%-34.19%8/9/2024 (Estimated)Latest IMCC, MTEX, GRTX, and PRPO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2024Q1 2024MTEXMannatechN/A$0.63+$0.63$0.63N/A$29.39 million5/14/2024Q1 2024PRPOPrecipioN/A-$1.46-$1.46-$1.46N/A$3.43 million5/13/2024Q1 2024GRTXGalera TherapeuticsN/A-$0.08-$0.08-$0.08N/AN/A5/8/2024Q1 2024IMCCIM Cannabis-$0.16-$0.16N/A-$0.01$7.84 million$8.95 million3/29/2024Q4 2023PRPOPrecipioN/A-$0.41-$0.41-$1.70N/A$4.33 million3/28/2024Q4 2023GRTXGalera TherapeuticsN/A-$0.10-$0.10-$0.10N/AN/A3/28/2024Q4 2023IMCCIM Cannabis-$0.16-$0.18-$0.02-$0.18$7.59 million$7.86 million3/28/2024Q4 2023MTEXMannatechN/A-$0.94-$0.94-$0.94N/A$32.69 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGRTXGalera TherapeuticsN/AN/AN/AN/AN/AIMCCIM CannabisN/AN/AN/AN/AN/AMTEXMannatech$0.202.50%-11.14%N/A N/APRPOPrecipioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRTXGalera TherapeuticsN/A7.547.54IMCCIM Cannabis0.050.650.40MTEXMannatech0.091.080.56PRPOPrecipio0.010.780.62OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRTXGalera Therapeutics50.77%IMCCIM Cannabis7.68%MTEXMannatech12.98%PRPOPrecipio10.45%Insider OwnershipCompanyInsider OwnershipGRTXGalera Therapeutics6.90%IMCCIM CannabisN/AMTEXMannatech41.50%PRPOPrecipio10.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableGRTXGalera Therapeutics754.39 million50.64 millionOptionableIMCCIM Cannabis9513.39 millionN/ANot OptionableMTEXMannatech2131.88 million1.10 millionNot OptionablePRPOPrecipio511.47 million1.31 millionNo DataIMCC, MTEX, GRTX, and PRPO HeadlinesRecent News About These CompaniesJune 5, 2024 | americanbankingnews.comPrecipio (NASDAQ:PRPO) Stock Passes Below 200-Day Moving Average of $6.32May 15, 2024 | msn.comPRPO Stock Earnings: Precipio Misses EPS, Misses Revenue for Q1 2024May 6, 2024 | globenewswire.comPrecipio Secures a short-term $500K Credit FacilityApril 20, 2024 | finance.yahoo.comPrecipio, Inc. (PRPO) Latest Stock News & Headlines - Yahoo FinanceApril 19, 2024 | morningstar.comPrecipio Inc PRPOMarch 25, 2024 | globenewswire.comPrecipio Announces Year end 2023 Shareholder Update CallMarch 12, 2024 | ca.finance.yahoo.comPrecipio, Inc. (PRPO)February 23, 2024 | benzinga.comPrecipio Stock (NASDAQ:PRPO), Analyst Ratings, Price Targets, PredictionsFebruary 13, 2024 | finance.yahoo.comPrecipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoYFebruary 6, 2024 | finanznachrichten.dePrecipio, Inc.: Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen Portfolio of Molecular assays for CancerJanuary 23, 2024 | msn.comPrecipio’s Q4 cash burn from operations drops below $100K for full quarterJanuary 23, 2024 | finanznachrichten.dePrecipio, Inc.: Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarterJanuary 23, 2024 | finance.yahoo.comPrecipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarterJanuary 17, 2024 | finanznachrichten.dePrecipio, Inc.: Precipio Signs Distribution Agreement For IV-Cell and HemeScreen in JapanJanuary 17, 2024 | finance.yahoo.comPrecipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in JapanJanuary 2, 2024 | finance.yahoo.comPrecipio Announces Christina Valauri joins the Board of DirectorsDecember 15, 2023 | finanznachrichten.dePrecipio, Inc.: Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024December 14, 2023 | finance.yahoo.comPrecipio Management Shares Thoughts on 2023, and Looks Ahead To 2024November 18, 2023 | cbonds.comPrecipio: Regulation Fd Disclosure, Financial Statements And ExhibitsOctober 18, 2023 | finance.yahoo.comPrecipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022New MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsGalera TherapeuticsNASDAQ:GRTXGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.IM CannabisNASDAQ:IMCCIM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.MannatechNASDAQ:MTEXMannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.PrecipioNASDAQ:PRPOPrecipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
